In this article Bridgette " Melo, 5, prepares for her inoculation of one of two reduced 10 ug doses of the Pfizer BioNtech COVID-19 vaccine during a trial at Duke University in Durham, NC on September 28, 2021 in a still image from the video Shawn Rocco | Duke University | via Reuters
The US government will rely heavily on pediatricians and family physicians in rolling out the Covid-19 vaccine to children aged 5 to 11, starting as early as next month, said Wednesday White House Coronavirus Response Coordinator Jeff Zients.
The White House has asked governors to enroll pediatricians and other providers in theImmunization programs so that they can begin administering vaccines as soon as doses are cleared by US regulators for use in young children, Zients told reporters.
Federal officials at health have also asked states to plan the implementation of awareness and education campaigns, Zients said, and to ensure Covid vaccination sites are available in areas of "high social vulnerability " and in rural areas.
"If cleared by the FDA and CDC, we'll be ready," Zients said during a press briefing on the pandemic. "We have the supply. I want to stress that this is a different supply; the dose for children is a different dose than for adults.
Parents say they are eager to get their children vaccinated like k IDs have started the new school yearwith the delta variant still booming across America. The number of new cases of Covid in children remains unusually high, with more than 750,000 child cases added in the past four weeks, according to the American Academy of Pediatrics.
For the The week ending Oct. 7, children accounted for 24.8% of weekly reported Covid cases, even though they represent around 22% of the U.S. population, according to the group. Infections in children account for 16.3% of all Covid cases since the start of the pandemic, the academy said.
Pfizer has "asked Thursday to the Food and Drug Administration to authorize the Covid vaccine that the drug maker developed with BioNTech for "children aged 5 to 11.
The company has submitted data which "showed a two dose regimen of 10 micrograms, or one-third of the dose used for adults and children 12 years and older - is safe and generates a strong immune response in a clinical trial in young children. He said the injections were well tolerated and produced a immune response and side effects comparable to those seen in a study of people aged 16 to 25.
Vaccinations for young children could begin in early November, pending a favorable review by regulators, U.S. Surgeon General Dr. Vivek Murthy said Wednesday.
A key FDA vaccine advisory committee is set to meet on October 26 to discuss Pfizer and BioNTech's vaccine data on the children, followed by one for the meeting of the advisory group on the control and prevention ofillnesses on November 2. If all goes well, the doses could be distributed in the days following the November meeting, he told reporters.